Chimeric Autoantibody Receptor- and/or Peptide-MHC-Based CAR Therapies for Targeted Elimination of Antigen-Specific B or T Cells in Hypersensitivity Disorders Such as Allergies and Autoimmune Diseases
Cells · 2025
DOI: 10.3390/cells14100753 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Isidora Protić-Rosić und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, 1090 Vienna, Austria. Hauptthemen laut MEDLINE: T-Lymphocytes, Receptors, Chimeric Antigen, Autoimmune Diseases, B-Lymphocytes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Country of Lower Austria, Medical University of Vienna.
Abstract (Originalsprache)
Hypersensitivity reactions are dysregulated and potentially devastating immune responses, characterized by a tendency to become chronic. They target either self-proteins or harmless foreign proteins and are driven by both T and B cells. Although numerous symptomatic treatment options for hypersensitivity reactions have been established over recent decades, only a few antigen-specific, causal approaches capable of specifically targeting the pathogenic autoreactive T and/or B cells have been developed. Among these are cell-based treatment modalities involving chimeric antigen receptor (CAR)- or chimeric autoantibody-receptor (CAAR)-expressing cells. These therapies utilize B- or T-cell antigens, presented as B-cell epitopes or peptide-major histocompatibility complexes (pMHCs) to serve as bait. The latter are coupled to potent activation domains derived from the TCR/CD3 complex itself, such as the zeta or CD3 chains, as well as domains from bona fide co-stimulatory molecules (e.g., CD28, 4-1BB). Recent in vitro and in vivo studies have demonstrated the therapeutic potential of these ATMP-based strategies in eliminating autoreactive lymphocytes and alleviating hypersensitivity reactions. This systematic review provides a comprehensive overview of the current status of antigen-specific CAR and CAAR T-cell therapies, highlighting novel directions as well as the ongoing challenges within this promising research field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, 1090 Vienna, Austria.
- Faculty of Chemistry, University of Belgrade, 11000 Belgrade, Serbia.
- University Library, Medical University of Vienna, 1090 Vienna, Austria.
- Karl Landsteiner University of Health Sciences, 3500 Krems, Austria.
ORCID-Profile: Isidora Protić-Rosić, Al Nasar Ahmed Sehgal, Sebastian Wrighton
Förderung
- Country of Lower Austria
- Medical University of Vienna
Zitieren
APA
Protić-Rosić, I., Sehgal, A. N. A., Wrighton, S., Heller, B., & Pickl, W. F. (2025). Chimeric Autoantibody Receptor- and/or Peptide-MHC-Based CAR Therapies for Targeted Elimination of Antigen-Specific B or T Cells in Hypersensitivity Disorders Such as Allergies and Autoimmune Diseases. Cells. https://doi.org/10.3390/cells14100753
Vancouver
Protić-Rosić I, Sehgal ANA, Wrighton S, Heller B, Pickl WF. Chimeric Autoantibody Receptor- and/or Peptide-MHC-Based CAR Therapies for Targeted Elimination of Antigen-Specific B or T Cells in Hypersensitivity Disorders Such as Allergies and Autoimmune Diseases. Cells. 2025. doi:10.3390/cells14100753
BibTeX
@article{ProtiRosi2025,
author = {Protić-Rosić, Isidora and Sehgal, Al Nasar Ahmed and Wrighton, Sebastian and Heller, Birgit and Pickl, Winfried F},
title = {Chimeric Autoantibody Receptor- and/or Peptide-MHC-Based CAR Therapies for Targeted Elimination of Antigen-Specific B or T Cells in Hypersensitivity Disorders Such as Allergies and Autoimmune Diseases},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14100753}
}
EUVIMED